|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0021107,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0205219,
umls-concept:C0253563,
umls-concept:C0950902,
umls-concept:C1322815,
umls-concept:C1442837,
umls-concept:C1696465,
umls-concept:C1707689,
umls-concept:C1956346,
umls-concept:C2348535
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-8-12
|
|
pubmed:abstractText |
Despite the availability of several potent antithrombotic agents, the optimal antiplatelet regimen in elective patients undergoing complex percutaneous coronary interventions is still debated. Aim of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial will be to assess the safety and efficacy of routine usage of the glycoprotein IIb/IIIa inhibitor eptifibatide in patients already treated with aspirin and clopidogrel and undergoing implantation of at least two drug-eluting stents in the same lesion, thus identifying a clinically stable but anatomically complex patient subset.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1558-2027
|
|
pubmed:author |
pubmed-author:Biondi-ZoccaiGiuseppe G LGG,
pubmed-author:ClementiFabrizioF,
pubmed-author:ColomboAntonioA,
pubmed-author:LettieriCorradoC,
pubmed-author:MargheriMassimoM,
pubmed-author:MarzocchiAntonioA,
pubmed-author:PratiFrancescoF,
pubmed-author:RomeoFrancescoF,
pubmed-author:SangiorgiGiuseppeG,
pubmed-author:SardellaGennaroG,
pubmed-author:SheibanImadI,
pubmed-author:StabileAmerigoA,
pubmed-author:ValgimigliMarcoM,
pubmed-author:VioliniRobertoR,
pubmed-author:VischiMassimoM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
957-62
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18695440-Angioplasty, Balloon, Coronary,
pubmed-meshheading:18695440-Coronary Artery Disease,
pubmed-meshheading:18695440-Creatine Kinase, MB Form,
pubmed-meshheading:18695440-Drug-Eluting Stents,
pubmed-meshheading:18695440-Endpoint Determination,
pubmed-meshheading:18695440-Female,
pubmed-meshheading:18695440-Humans,
pubmed-meshheading:18695440-Male,
pubmed-meshheading:18695440-Peptides,
pubmed-meshheading:18695440-Platelet Aggregation Inhibitors,
pubmed-meshheading:18695440-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:18695440-Research Design,
pubmed-meshheading:18695440-Single-Blind Method
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
|
|
pubmed:affiliation |
Interventional Cardiology, Division of Cardiology, University of Turin, Turin, Italy.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
